Data published in the Journal of American College of Cardiology
shows that this novel form of vitamin B3 helps maintain mitochondrial
function in an animal model by stimulating a cellular repair pathway;
preliminary human data also support future testing of NR in connection
with cardiac health
LOS ANGELES--(BUSINESS WIRE)--Apr. 9, 2019--
ChromaDex
Corp. (NASDAQ:CDXC) today reported that results of a new preclinical
study showed that supplementation with the unique B3 vitamin
nicotinamide riboside (NR, or Niagen®) helps maintain heart function in
mice by stimulating a conserved cellular response called the
“mitochondrial unfolded protein response” (UPRmt) that helps
maintain mitochondrial function. The study also presents preliminary
human data to support future testing of NR in humans. Conducted by
Principal Investigators Prof. Ajay M. Shah and Dr. Ioannis Smyrnias,
Kings College London, the independent study results were published
yesterday in the Journal of the American College of Cardiology (JACC).
This study follows clinical
results from last year highlighting the potential for NR
supplementation to improve cardiovascular health.
“NR supplementation is a new and exciting intervention that merits
testing in the human treatment of heart failure and other cardiac
conditions,” said Prof. Shah. “These study findings showing the
potential of NR to activate UPRmt are extremely encouraging
and merit further research into the potential for NR to impact human
cardiac health.”
In several complementary experiments, the authors found that increasing
NAD levels with NR stimulated the UPRmt in cells and mice.
Additionally, NR helped improve mitochondrial function and maintained
the heart’s ability to pump blood. To begin to investigate whether these
findings might translate to humans, the study authors collected heart
tissue samples from people and found positive correlations between
increased UPRmt activation and markers of healthy heart
function. Human studies were performed under institutional ethical
approval and with informed consent.
NR is clinically proven to boost NAD, a critical coenzyme for cellular
energy production and mitochondrial function. Previous research has
demonstrated that NR can improve mitochondrial and cardiac function in
mice, and multiple clinical studies are currently registered to
investigate the possible effects of NR in heart failure patients. This
preclinical study provides new insight into the relationship between NR,
mitochondrial function, and cardiac stress.
“There is a significant and fast-growing body of data supporting the
health benefits of Niagen and our consumer product Tru Niagen,” said
ChromaDex CEO Rob Fried. “This important study underscores the role that
Niagen may play in human heart health and we look forward to further
research.”
To date, ChromaDex has pioneered NAD research by investing millions of
dollars in safety and human clinical trials on its patent-protected NR
(commercially known as Niagen). ChromaDex has supplied Niagen at no cost
to more than 160 leading institutions for research, including Dartmouth,
the National Institutes of Health, University of Iowa, and the Scripps
Research Institute.
For additional information on the science supporting Niagen visit www.chromadex.com.
About ChromaDex:
ChromaDex
Corp. is a science-based integrated nutraceutical company devoted to
improving the way people age. ChromaDex scientists partner with leading
universities and research institutions worldwide to uncover the full
potential of NAD and identify and develop novel, science-based
ingredients. Its flagship ingredient, NIAGEN®
nicotinamide riboside, sold directly to consumers as TRU
NIAGEN®, is backed with clinical and scientific research, as well as
extensive IP protection. TRU
NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a
website at www.chromadex.com to
which ChromaDex regularly posts copies of its press releases as well as
additional and financial information about the company.
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities and Exchange Act of 1934, as amended, including
statements related to the timing and results of future NR studies, and
whether NR may benefit patients with heart failure or benefit heart
health. Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not always, be
identified by the use of such words as "expects", "anticipates",
"intends", "estimates", "plans", "potential", "possible", "probable",
"believes", "seeks", "may", "will", "should", "could" or the negative of
such terms or other similar expressions. More detailed information about
ChromaDex and the risk factors that may affect the realization of
forward-looking statements is set forth in ChromaDex’s Annual Report on
Form 10-K for the fiscal year ended December 31, 2018, ChromaDex's
Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex
to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof, and
actual results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are qualified
in their entirety by this cautionary statement and ChromaDex undertakes
no obligation to revise or update this release to reflect events or
circumstances after the date hereof. ChromaDex provided research
materials and a portion of the grant funding as a collaborator for the
study.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190409005440/en/
Source: ChromaDex Corp.
ChromaDex Media Contact:
Alex Worsham, Director of Strategic
Partnerships
949-648-3775
alexw@chromadex.com
ChromaDex Investor Relations Contact:
Brianna Gerber, Sr.
Director of FP&A and Investor Relations
949-344-3782
briannag@chromadex.com